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Abstract
Background: Up to 10% of individuals with breast cancer (BC) belong to families 
with hereditary syndromes. The aim of this study was to develop an instrument to 
identify individuals/families at high-hereditary risk for BC and offer dedicated sur-
veillance programs according to different risks.
Methods: The instrument consisted of a primary questionnaire collecting history of 
BC and ovarian cancer (OC). This questionnaire was applied to women enrolled in 
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1 |  INTRODUCTION
Hereditary breast ovarian cancer (HBOC) can be defined 
as a genetic disorder in which breast and ovarian malignant 
tumors seem to cluster within families.1 The main factors 
that suggest a hereditary cancer predisposition syndrome 
are young age at cancer diagnosis, multiple tumors, bilateral 
tumors, presence of rare tumors, several cancer-affected rel-
atives, autosomal dominant inheritance and, in some cases, 
ethnicity.2-7 Families with these characteristics should be 
referred to specialized hospital/centers that offer cancer risk 
assessment and genetic counseling8-10
In Italy, most cancer genetic services are largely distrib-
uted in the country but they are not regulated by the national 
health system rules.11
Therefore, there is limited knowledge regarding the prev-
alence of HBOC predisposition syndromes in the Italian 
population, which has already reached more than 60 million 
people.12 Moreover, considering the high probability of de-
veloping cancer in individuals with hereditary cancer pre-
disposition and the fact that presymptomatic identification 
of at-risk individuals offers enormous potential for reducing 
cancer-related risk,13 a better understanding of the preva-
lence of hereditary cancer predisposition syndromes in Italy 
is imperative.
In this context, the goal of this study was to develop a 
pilot instrument for identifying individuals and families who 
are at risk for hereditary BC in a regional screening popula-
tion-based sample from Emilia-Romagna, Italy.
2 |  PATIENTS AND METHODS
2.1 | Ethical aspects
Our program was approved and deliberated by the Emilia-
Romagna region under the protocol number RER 220/2011.14 
Furthermore, an informed consent form was signed by each 
woman who participated in the study for the genetic testing 
analysis and it was approved by the Ethics Committee of 
each Hub center.
2.2 | Population of the study
Since January 2012 until December 2016, the regional program 
for HBOC started in Emilia-Romagna. Women attending the 
Regional Breast Cancer Screening Program (RBCSP), which 
begins at 45 years with an annual mammogram until 50 years 
and then continues until 74 years with biyearly mammogram, 
were interviewed by a questionnaire regarding their personal 
or family history of BC and OC from radiologist technicians. 
The interview was repeated every screening round to verify 
changes in the family history. At January 2019, women living 
in Emilia-Romagna region, aged between 45 and 74 years, are 
960 792. About 69% of them adhere to the RBCSP that is dis-
tributed in 8 different units along the region.15
Women who asked for their risk at the General Practioner 
(GP) received the same questionnaire too. Finally, also some 
specialists, the gynecologists, oncologists, and radiologists, 
the Emilia-Romagna Breast Cancer Screening Program. General practitioners (GPs) 
and specialists could propose the same questionnaire too. Women with a score of ≥ 2, 
were invited to complete an oncogenetic counseling. According to the Tyrer-Cuzick 
evaluation, women considered at high risk were invited to involve the most represent-
ative alive individual of the family affected with BC/OC for BRCA1/2 genetic testing.
Results: Since January 2012 and December 2016, 660 040 women were evaluated 
by the regional screening program, of which 22 289 (3.5%) were invited to the Spoke 
evaluation, but only 5615 accepted (25.2%). Totally, also considering women sent 
by GPs and specialists, 11 667 were assessed and 5554 were sent to the Hub evalu-
ation. Finally, 2342 (42.8%) women fulfilled the criteria for genetic testing, and 544 
(23.2%) resulted BRCA1/2 mutation carriers.
Conclusions: To our knowledge, this is the first regional population-based multistep 
model that is aimed to identify individuals with BRCA1/2 mutations and to offer an 
intensive surveillance program for hereditary-high risk women. This tool is feasible 
and effective, even if more efforts must be performed to increase the acceptance of 
multiple assessments by the study population.
K E Y W O R D S
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could administer the same questionnaire in the case of posi-
tive family history.
2.3 | Primary screening questionnaire
The primary questionnaire was based on typical criteria for 
hereditary breast and ovarian cancer, that is, young age at 
onset, bilateral breast cancer (BC), association with ovarian 
cancer (OC) and relationship with other affected patients. 
These criteria were already considered as pathognomonic 
of hereditary breast cancer syndrome by Lynch.16 The ques-
tionnaire contained a grid that assigned a score from 0 to 2; 
women who reached the total score of ≥ 2 were invited to 
ask for the Spoke evaluation. The grid was adopted since 
2000, by the Biosciences Laboratory of Istituto Scientifico 
Romagnolo per lo Studio e la Cura dei Tumori (IRST), in 
Meldola, identifying 22% of patients with BRCA1/2 muta-
tions among families with characteristics of hereditary breast 
and ovarian cancer.17 This rate was considered cost-effective 
as indicated by the ASCO guidelines.18
In addition, a personal or family history of male BC, of 
BC and OC in the family or in the same patient, of early onset 
BC (≤35  years), of  bilateral BC at ≤50  years, of  not mu-
cinous and not borderline sporadic OC, of two first-degree 
relatives affected by BC, of which one arisen at ≤40 years or 
bilateral, and of triple negative BC (≤ 60 years), represented 
a direct criterion for Hub evaluation. The majority of the pri-
mary questionnaires was administered by the radiology tech-
nicians at the single unit of the RBCSP, uploading the grid 
score whenever the patient entered into the mammography 
room. All questionnaires were collected on a dedicated soft-
ware program that calculates the score in real time and col-
lects the results on a specific single database for each patient. 
Also, GPs had the same grid uploaded on their regional elec-
tronic health system and autonomously calculated the score 
when the patient was visited for the first time. The grid was 
also held by other specialists such as gynecologists, oncol-
ogists, and radiologists, but they rarely offered this evalua-
tion to their patients. No informed consent was signed at this 
time. No central evaluation was performed to calculate the 
score obtained by different patients.
The questionnaire is shown in Table 1.
2.4 | Spoke model
All healthy women with score ≥ 2 or patients affected with 
BC at the age ranging between 36 and 40 years were invited 
to refer to their own Spoke center. In case of women at-
tending the RBCSP eligible for further assessment, they re-
ceived a letter with the mammography result and the phone 
number for calling the own Spoke center. In case of eligi-
bility defined by GPs or other specialists, the appropriate 
Spoke center phone number was directly given to the pa-
tient. Totally 13 centers in Emilia-Romagna were accredited 
as Spoke centers. At the Spoke Center, either geneticists or 
oncologists trained in oncogenetic counseling collected in-
formation on the cancer family history and drawn the pedi-
gree. In both cases a specific informed consent was obtained 
aimed to receive family history information. The risk of BC 
was calculated with the Tyrer-Cuzick program.19
2.5 | Tyrer-Cuzick risk calculation
The Tyrer-Cuzick evaluation collects personal informa-
tion regarding woman's age, menarche's age, height and 
T A B L E  1  Family risk evaluation
Age at Onset
BC OC
<40 y 40-49 y Bilateral 40–49 y Monolateral 50-59 y >60 y Every
Woman 2 2 1 1 0 2
Mother 2 2 1 1 0 1
Sister 2 2 1 1 0 1
Daughter 2 2 1 1 0 1
Paternal Grandmother 2 2 1 1 0 1
Paternal Aunt 2 2 1 1 0 1
Maternal Grandmother 1 1 1 0 0 1
Maternal Aunt 1 1 1 0 0 1
Relative with MBC 2 2 2 2 2 -
Cousin (daughter of father's 
brother)
1 0 0 0 0 1
Nephew 1 1 1 0 0 1
Abbreviations: BC, breast cancer; MBC, male breast cancer; OC, ovarian cancer.
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weight measurements, parity, previous breast lesions, and 
menopausal status. Further information with regard to fam-
ily history of BC or OC in the relatives is also collected. 
The final calculation provides the 10-year risk and the 
life-time risk for BC in individual and general population, 
respectively.
Women with a life-time risk of developing BC at most 
1 time more than general population were considered at 
low risk (LR) and were offered RBCSP. Women with a 
risk ranging between two and three times more than gen-
eral population, were considered at intermediate profile 
and followed with an annual mammogram, associated 
with ultrasound, in the case of dense breasts since 40 until 
45 years and then referred to the RBCSP. Women with a 
risk more than three times (profile 3 or high) were evalu-
ated for referring to the Hub center with the aim to perform 
gene test analysis.
This model assessment was chosen among different risk 
calculators, that is, Gail, Claus, Ford, and manual model. It 
looked to be likely the most sensitive model to select women 
at high risk, apart from the lack of male breast cancer family 
history evaluation.20 However, women who were sent to the 
Hub center were further evaluated for BRCA1/2 genetic test-
ing according to the Modena criteria.21
2.6 | Hub model
Four regional Hub centers were accounted in Emilia-Romagna. 
The referral to the Hub centers was proposed in the case of 
profile 3 at the Spoke evaluation or in the case of direct crite-
ria at the primary screening, as previously mentioned.
At the Hub evaluation, a family history of:
1. Early Onset BC
2. BC and OC in the same patient or in other members
3. Male BC
4. Triple Negative BC at ≤60 years
5. OC not mucinous not borderline
6. Two or more BC in the family with a first-degree rela-
tionship each other and young age at onset (≤40 years) or 
bilateral BC
was considered eligible for genetic testing and the most in-
dicative affected patient in the family was invited to undergo 
pretest oncogenetic sessions, aimed to perform BRCA1/2 anal-
ysis. In a period of 3-4 weeks, the BRCA1/2 results were re-
leased along with a posttest genetic session. When a positive 
test was found, relatives of the index case were invited to un-
dergo specific mutation analysis. All positive women already 
affected or not, were offered a screening protocol with six-
monthly breast ultrasound since 18 to 69 years, annual breast 
MRI since 25 until 74 years, annual mammogram since 35 to 
69 years and biennial in the 70-74 years range. In the case of 
bilateral mastectomy, only breast ultrasound every six months 
was proposed since the residual cancer risk remains equal to 
4%-5% and no guidelines are provided for breast MRI screen-
ing utility in this group of women. Breast ultrasound seemed 
to have a good ratio between cost and effectiveness rather 
than a solely clinical examination in order to recognize little 
foci of cancer upon the protheses. For OC screening, a six-
monthly transvaginal ultrasound plus Ca.125 marker dosage 
was proposed, when patients refused to consider the prophy-
lactic oophorectomy or when they were too young to offer. 
The six-monthly transvaginal ultrasound plus Ca.125 marker 
dosage was offered on the basis of data obtained by a phase II 
study in which OC screening performed more frequently than 
annually with prompt surgical intervention seemed to offer a 
better chance of early-stage detection in high-risk women.22 In 
the case of previous OC, only Ca.125 marker dosage every six 
months was offered.14
However, when criteria or individual disposable for gene 
testing lacked, a dedicated screening protocol was offered to 
women with different risk profiles; in the case of high risk 
(profile 3) it starts at 25 years of age with six-monthly ultra-
sound until 49, annual mammogram since 35 to 69 years and 
then biennial until 74  years. For LR and intermediate risk 
(IR), the screening protocol was described above.14 The sur-
veillance protocol is detailed in Table 2. The process map-
ping of patients through Spoke and Hub screening procedure 
is shown in Figure 1.
2.7 | Genetic testing
Genetic testing for identifying BRCA1 and BRCA2 mutations 
included the Next Generation Sequencing (NGS) on the entire 
codifying sequence and the Multiplex Ligation Polymerase 
Analysis (MLPA) for rearrangements of BRCA1/2 gene. The 
variants were divided, according to the ENIGMA classifica-
tion, in five classes: C5 and C4 were considered as positive 
results and carriers were followed as previous reported. In 
the case of C3, C2, and C1 results, the screening was based 
on the risk profile defined by the Tyrer-Cuzick risk model. 
For the C3 classes, a customized pipeline for variant call-
ing was questioned every month in order to find an eventual 
reclassification.
3 |  RESULTS
3.1 | Primary screening questionnaire
From January 2012 to December 2016, among 660  040 
women participating in the RBCSP, 659  747 women an-
swered the questionnaire, whereas 293 (0.04%) refused to 
   | 5CORTESI ET al.
compile the same. Totally, 22 289 women (3.5%) received 
the letter and were invited to refer to the own Spoke center. 
By dividing all women in quintiles for age from 45 to 
74 years, 8518 of those invited to call on the Spoke evalu-
ation ranged between 45 and 49  years (38.2%). Detailed 
information on classes of age, number, and percentage of 
patients referred to the Spoke center by RBCSP can be 
found in Table 3.
3.2 | Spoke evaluation
Among all, 22 289 women were referred to the Spoke by 
the RBCSP, only 5615 (25.2%) phoned for having a Spoke 
evaluation. All requests were held in about 2 weeks. In ad-
dition, 2258 (19.4%) women were referred by GPs and 3794 
(32.5%) by specialists to the Spoke centers, with the remain-
ing women (48.1%) coming from RBCSP. Women referred 
by GPs were, in about one-quarter of cases, younger than 
35  years of age (560/2258, 24.8%), whereas specialists 
identified more patients in the age 40-44 years (887/3794, 
23.4%). Totally, 11 667 women arrived at the Spoke cent-
ers. Among those, 330 refused to complete the assessment, 
and the remaining 11 337 women were evaluated. Totally, 
4627 women evaluated were considered eligible for the Hub 
referral (40.8%), whereas 6710 (59.2%) had an IR or LR 
profile. Data on source, age and risk profile are reported in 
Table 4.
Among all 11 667 women who made an appointment at the 
Spoke center, 1400 (12%) were very young (<35 years), 2570 
(22%) ranged between 35 and 44 years of age, whereas 7697 
(66%) were aged from 45 to 74 years. Out of 3970 women aged 
less than 45 years, 2449 (61.7%) were sent at the Spoke Center 
by specialists, 1472 by GPs (37.1%) and 49 by RBCSP (1.2%).
3.3 | Hub evaluation
Out of 4627 women assessed as HR (profile 3), only 2815 
(60.8%) accepted the Hub evaluation. The most proportion of 
women eligible for the Hub evaluation was identified by GPs 
(1205/2241, 53.8%), followed by specialists (1768/3684, 
48.0%) and finally by RBCSP (1654/5412, 30.6%) as shown 
in Table 5.
Additionally, following the seven criteria considered as 
enough for to the Hub referral at the primary questionnaire, 
2739 women were sent directly, without the Spoke assess-
ment. Totally, 5554 women received a Hub evaluation.
In 2342 cases (42.2%), a genetic test was performed, 
whereas 3212 (57.8%) women did not meet criteria for 
BRCA1/2 analysis. Five hundred and forty-four women 
(23.2%), resulted BRCA1/2 mutation carriers. As expected, 
among BRCA1/2 mutated women, the highest rate of mu-
tations was found in very young women, aged less than 
30  years, (35%); the positive rate decreased until 18% in 
women ranging between 55 and 59 years. Women without 
mutation ascertained were classified as having profiles 1, 2, 
or 3 according to the previous Tyrer-Cuzick risk calculation. 
Table 6 reports data on women who underwent a genetic 
test. The number of patients along the process mapping is 
depicted in Figure 2.
4 |  DISCUSSION
Our model is an effective tool to identify individuals/families 
at risk for BC, in a population-based sample. In fact, nearly 
all women attending the RBCSP, with the exception of 293 
cases (0.04%), compiled the primary questionnaire, also tak-
ing into account the change of family history along time. This 
T A B L E  2  Surveillance program for different risk profiles
Risk profile Start US MX MRI
Profile 1 45 y If suspected mammogram image 45-50 y Aa
51-74 y Bb
(Population Screening)
 
Profile 2 25 y (if relative with 
EOBCc)
36 y
>41 y if high breast density or 
suspected mammogram image
40-50 y Aa
51-74 y Bb
(Population Screening)
According to 
EUSOMA guidelines
Profile 3 (without detected 
mutations)
25 y 25-60 y Sd 35-69 y Aa
70-74 y Bb
According to 
EUSOMA guidelines
Profile 3 (with detected 
mutations)e
From the mutation 
detection
From the mutation 
detection-69 y Sd
35-69 y Aa
70-74 y Bb
>25 y A
aAnnual 
bBiennial 
cEarly Onset Breast Cancer 
dSemestral 
eCa.125 and Transvaginal Ultrasound every 6-months was also added 
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multistep tool, proposed by a healthcare staff, provides more 
awareness about hereditary BC than a recently developed 
nurse navigator approach, by which a low participation of 
screening patients requesting HBOC education and evalua-
tion occurred (9%).23
Hoskins et al,24 previously validated a tool for each case 
of BC or OC arbitrarily selected, weighting more points 
for patients with features associated with a higher prob-
ability that a BRCA mutation is present: early age of BC 
diagnosis, OC diagnosis, male BC in the family.25-29 The 
authors analyzed a total of 3906 women without a personal 
history of BC presenting for a screening mammogram at 
a community hospital, identifying 86 (2.2%) women with 
a family history indicative of a high probability (>10%) 
that a BRCA mutation was present. The percentage of at-
risk families was superimposable to our selection model in 
which 22 289 (3.5%) women were eligible for a secondary 
screening step.
F I G U R E  1  The flowchart of patients through the Spoke and Hub screening procedure. BC, breast cancer; GP, general practitioner; HR, high 
risk; IR, intermediate risk; LR, low risk; RBCSP, Regional Breast Cancer Screening Program
Woman attending the RBCSP Woman who asks her GP or specialist about the BC risk
Grid compilation 
Total score
<2
No further assessments 2 sent to the Spoke evaluation
Criteria for 
Hub 
assessment 
Tyrer-Cuzick model for BC 
risk
RR <2 RR >2 e <3 RR >3 
LR IR HR
RBCSP IR Surveillance 
Genetic 
test 
criteriaHR surveillance 
without mutation
NO YES Hub evaluation
NO Index case 
Disposable for
 test 
-
no
Yes BRCA1/2 test in
 patient
Yes
C5 or C4 variant
Radiological and gynecological
Surveillance for HR with mutation
Targeted BRCA test
Negative
Referral to Hub center for take care
Positive
Breast and Ovarian 
Prophylactic surgery
Relatives invitation
Signature of informed consent 
  Signature 
of 
informed 
consent NO
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An added value of this multistep process has been pro-
vided by GPs and specialists involvement. A recent system-
atic review on 40 studies published between 1996 and 2017, 
has evaluated the effects on patients of genetic cancer risk 
assessment in general practice.30 A variety of testing and 
screening tools were available for genetic cancer risk assess-
ment in general practice, principally for breast-ovarian, but 
GPs often reported low knowledge about hereditary cancers 
even if, time along, they were increasingly interested. In our 
experience too, the lowest percentage of women sent to the 
Spoke evaluation, came from GPs (19.4%) with respect to 
specialists (32.5%) and RBCSP (48.1%). However, GPs and 
T A B L E  3  Women refer to Spoke evaluation by RBCSP 
according to the age
Total No Age %
8518 45-49 38.2
3836 50-54 17.2
2856 55-59 12.8
2511 60-64 11.3
2354 65-69 10.6
2214 70-74 9.9
22 289 All 100
T A B L E  4  Characteristics of women arrived at the Spoke centers
Age GPs Specialists RBCSP Total % Refuse LR IR HR
<35 560 840 0 1400 12 32 237 424 707
35-39 403 722 0 1125 9.6 26 191 365 543
40-44 509 887 49 1445 12.4 35 309 453 648
45-49 246 432 1832 2510 21.5 96 835 663 916
50-54 214 369 1153 1736 14.9 48 612 423 653
55-59 140 234 861 1235 10.6 28 458 260 489
60-64 100 146 743 989 8.5 26 409 234 320
65-69 65 102 599 766 6.6 30 339 180 217
70-74 21 62 378 461 4 9 210 108 134
Total 2258 3794 5615 11 667 100 330 3600 3110 4627
Abbreviations: HR, High Risk; IR, Intermediate Risk; LR, Low Risk.
T A B L E  5  Characteristics of women assessed at the Hub centers
  <35 Hub % 35-44 Hub % 45-74 Hub % Total Hub referral %
GPs 556 289 52.0 909 473 52.0 776 443 57.1 2241 1205 53.8
Specialists 812 418 51.5 1552 699 45.0 1320 651 49.3 3684 1768 48.0
RBCSP 0 0 0 48 19 39.6 5364 1635 30.5 5412 1654 30.6
Total 1368 717 52.4 2509 1191 47.5 7460 2729 36.6 11 337 4627 40.8
T A B L E  6  Characteristics of women underwent BRCA1/2 gene analysis
Age N° LR % LR N° IR % IR N° HR % HR N° BRCA1/2 % BRCA1/2 Total
<25 44 40 23 21 8 7 36 32 111
25-29 23 23 19 19 24 24 35 35 101
30-34 44 25 24 14 58 33 49 28 175
35-39 68 24 38 13 115 41 62 22 283
40-44 64 21 44 15 115 38 80 26 303
45-49 83 26 45 14 123 39 66 21 317
50-54 74 26 24 8 132 46 58 20 288
55-59 57 26 15 7 107 49 38 18 217
60-64 41 22 14 8 92 50 37 20 184
65-69 40 25 3 2 82 51 35 22 160
70-74 51 25 3 1 101 50 48 24 203
Total 589 25.1 252 10.8 957 40.9 544 23.2 2342
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specialists were needed to identify young high-risk individ-
uals, since the RBCSP begins at 45 years. In fact, 24.8% of 
women referred to the Spoke centers by GPs were younger 
than 35 years, such as women sent by specialists were mostly 
inclusive between 40 and 44 years (23.4%). As already seen 
in a recent paper that investigated the young women's per-
ceptions regarding communication with healthcare providers 
about BC risk, people aged 18-29 years asked more than doc-
tors about their risk, whereas women in the age group be-
tween 30 and 44 years were likely queried by GPs about their 
family history.31 Totally, only 34% of all women evaluated 
at the Spoke centers aged less than 45 years and this could 
represent a critical issue, in order to offer a very preventive 
strategy in young individuals at hereditary-HR for BC.
Another weakness was shown by the low rate of adhe-
sion to the Spoke evaluation among women eligible by the 
RBCSP (25.2%). The low rate of adherence to the second 
screening step could depend by the fact that the invitation 
was provided by the same letter in which the mammo-
gram result was delivered. Probably by this way, women 
focused their attention on negative mammogram results 
rather than on the deepening of their BC risk. An attempt 
to recover women eligible for the second screening step 
has been performed at the subsequent round, where the 
grid was repeated with a little increased rate of accep-
tance (0.3%). In a Brazilian study performed on 20  000 
women attending the mammogram screening program, a 
questionnaire regarding BC family history was proposed 
F I G U R E  2  Number of patients evaluated along the process mapping
659 747  women answered the  
quesonaire at the RBCSP
22 289(3.5%) women eligible for 
secondary screening step
5618 (23.7%)
accepted to adhere
invitaon
637 458 women were inegible for 
further screening
3798 (32.5%)
from Specialists
2251 (19.4%)
from  GPs
11 667 women at the
Spoke evaluaon
5554 women  
evaluated at the 
Hub
3212 (57.2%) w/o 
genec test
2342  (42.8%) with
Genec test
4627  (39.7%) had
high risk profile
6710 (60.3%) had
intermediate or low risk 
profile
544 (23.2%)
were BRCA1/2
660 040 women
parcipated to the 
RBCSP
293 refuse to answer
quesonaire
2815 (60.3%) 
accepted the Hub
evaluaon
2739 directly sent
According to the 
personal or family 
history
330 refuse the Spoke
evaluaon aer 
acceptance
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and 3121 (15.6%) were invited to the second phase of the 
study by a direct approach or by letter or by phone. The 
first two modalities of invitation provided a very low rate 
of adhesion (11.4% and 16%, respectively), lower than 
our rate of acceptance. The highest rate of adherence was 
reached by the phone call (72.6%), demonstrating the va-
lidity for this approach for identifying families at risk for 
BC.32 However, the telephone approach needs dedicated 
personnel, and expensive costs for a large regional screen-
ing program. Also, considering the recall carried out at 
the subsequent round, we concluded that women who did 
not attend the Spoke assessment did not want to know 
their BC risk, with respect to the nondirectiveness defined 
as procedures that promote and enhance the autonomy and 
self-control of patients.33
Nevertheless, among 11 337 women who received the 
Spoke evaluation, about 40% were HR, whereas 60% were 
considered as IR or LR. All LR (3600, 31.8%) and young 
IR women (aged 45 years or more, that is, 1868 equal to 
16.6%), did not receive any personal prevention screening 
program but were invited to attend the RBCSP starting at 
45 years. Only IR women aged less than 45 years (1294, 
11.4%) and all HR individuals (4627, 40.8%) were offered 
a dedicated screening program for no hereditary risk of BC. 
Totally, the regional Spoke assessment identified about 
half of the women (5921, 52.2%) who needed an intensive 
screening program. A recent analysis performed on 2177 
women at HR and IR followed at the Modena spoke center 
showed a BC detection rate of 8.5 and 16.1  ×  1000 per-
sons-years, respectively, which clearly increases in compar-
ison with the BC detection rate provided by the RBCSP.34 
This data confirms the usefulness of an intensive screening 
program for at-risk women and justifies a massive effort to 
identify the various parameters.
Once again, only 60% of women sent to the Hub centers 
accepted to be evaluated, but the rate of adherence was in-
creased with respect to the previous step, underlying more 
interest toward the knowledge of hereditary conditions. Of 
notice, 49% of women evaluated at the Hub centers skipped 
the Spoke assessment according to specific criteria at the 
primary questionnaire. Among 5554 women evaluated at 
the Hub centers, 42.8% were eligible for gene testing and 
23.2% resulted positive. This multistep approach provides a 
long patient journey, deriving a very high benefit in terms of 
BRCA mutation carrier identification. In fact, the step-by-
step process is able to select a shrinking number of women 
to be investigated by gene test analysis: this approach looks 
to be really cost-effective, although a recent study comparing 
BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1 
analysis performed in selected and unselected women, seems 
to prevent more BC and OC in the general population, with-
out previous selection.35 However, our mutation rate is in 
line with other series based on different eligibility criteria for 
HBOC, as referred in a recent review where the BRCA1/2 
mutation rate in early onset BC, triple negative BC, bilateral 
BC, and family history of BC is about 30%.36 It also means 
that direct criteria for the Hub evaluation represent a signif-
icant way to collect women who are potentially at risk for 
HBOC syndrome, avoiding a multistep process and saving 
time and important costs.
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